The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells

The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells

Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy 2023-05, Vol.65 (5)
Hauptverfasser: Tomita, Yuriko, Takeda, Makoto, Matsuyama, Shutoku
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page
container_title Antimicrobial agents and chemotherapy
container_volume 65
creator Tomita, Yuriko
Takeda, Makoto
Matsuyama, Shutoku
description Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….
doi_str_mv 10.1128/AAC.00020-21
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2495407631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2495407631</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-c8db597da267a62996d077ca8db8f12643bc41295ddeeb790a25427250419f5a3</originalsourceid><addsrcrecordid>eNo1kM9LwzAUx4Mgbk5vniVHL5lJ2ibNsRSdwkBw02tJm8RlZG3Nj4H-9Vacl_d93-_78Hg8AG4IXhJCy_uqqpcYY4oRJWdgTrAoESsEm4HLEPbTZDL4AsyyjOWCED4H--1OQ9lHi2xvXNL9t4RH61OAyqcPaOTRjtZP1cOdDNDZGJ2G2hjdRTj00OvR2U5GO_WDgZvqdYPq4R1RaHvYJReT1wp22rlwBc6NdEFfn3QB3h4ftvUTWr-snutqjUZCWURdqdpCcCUp45JRIZjCnHdyikszEXnWdjmholBK65YLLGmRU04LnBNhCpktwN3f3tEPn0mH2Bxs-L1A9npIoaG5KHLMWUYm9PaEpvagVTN6e5D-q_n_T_YDRNZkjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2495407631</pqid></control><display><type>article</type><title>The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Tomita, Yuriko ; Takeda, Makoto ; Matsuyama, Shutoku</creator><creatorcontrib>Tomita, Yuriko ; Takeda, Makoto ; Matsuyama, Shutoku</creatorcontrib><description>Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….</description><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.00020-21</identifier><identifier>PMID: 33649117</identifier><language>eng</language><publisher>United States</publisher><ispartof>Antimicrobial agents and chemotherapy, 2023-05, Vol.65 (5)</ispartof><rights>Copyright © 2021 Tomita et al.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33649117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tomita, Yuriko</creatorcontrib><creatorcontrib>Takeda, Makoto</creatorcontrib><creatorcontrib>Matsuyama, Shutoku</creatorcontrib><title>The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><description>Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….</description><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo1kM9LwzAUx4Mgbk5vniVHL5lJ2ibNsRSdwkBw02tJm8RlZG3Nj4H-9Vacl_d93-_78Hg8AG4IXhJCy_uqqpcYY4oRJWdgTrAoESsEm4HLEPbTZDL4AsyyjOWCED4H--1OQ9lHi2xvXNL9t4RH61OAyqcPaOTRjtZP1cOdDNDZGJ2G2hjdRTj00OvR2U5GO_WDgZvqdYPq4R1RaHvYJReT1wp22rlwBc6NdEFfn3QB3h4ftvUTWr-snutqjUZCWURdqdpCcCUp45JRIZjCnHdyikszEXnWdjmholBK65YLLGmRU04LnBNhCpktwN3f3tEPn0mH2Bxs-L1A9npIoaG5KHLMWUYm9PaEpvagVTN6e5D-q_n_T_YDRNZkjQ</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Tomita, Yuriko</creator><creator>Takeda, Makoto</creator><creator>Matsuyama, Shutoku</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20230501</creationdate><title>The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells</title><author>Tomita, Yuriko ; Takeda, Makoto ; Matsuyama, Shutoku</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-c8db597da267a62996d077ca8db8f12643bc41295ddeeb790a25427250419f5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tomita, Yuriko</creatorcontrib><creatorcontrib>Takeda, Makoto</creatorcontrib><creatorcontrib>Matsuyama, Shutoku</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tomita, Yuriko</au><au>Takeda, Makoto</au><au>Matsuyama, Shutoku</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>65</volume><issue>5</issue><eissn>1098-6596</eissn><abstract>Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….</abstract><cop>United States</cop><pmid>33649117</pmid><doi>10.1128/AAC.00020-21</doi></addata></record>
fulltext fulltext
identifier EISSN: 1098-6596
ispartof Antimicrobial agents and chemotherapy, 2023-05, Vol.65 (5)
issn 1098-6596
language eng
recordid cdi_proquest_miscellaneous_2495407631
source EZB-FREE-00999 freely available EZB journals; PubMed Central
title The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T08%3A28%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20anti-influenza%20virus%20drug%20favipiravir%20has%20little%20effect%20on%20replication%20of%20SARS-CoV-2%20in%20cultured%20cells&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Tomita,%20Yuriko&rft.date=2023-05-01&rft.volume=65&rft.issue=5&rft.eissn=1098-6596&rft_id=info:doi/10.1128/AAC.00020-21&rft_dat=%3Cproquest_pubme%3E2495407631%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2495407631&rft_id=info:pmid/33649117&rfr_iscdi=true